Unlocking the Diagnostic Potential of Tear Fluid
A proprietary platform for standardized tear biopsy, biomarker preservation, and AI-enabled molecular analysis.
"The eye is the window of the soul and the chief organ whereby the understanding may most fully and abundantly appreciate the infinite works of nature."
— Leonardo da Vinci
Tear fluid is an underexplored source of molecular information with significant potential for precision diagnostics. BioDrop is developing technologies that enable standardized collection and preservation of tear-derived biomarkers for downstream molecular analysis.
Why Tears?
Rich source of molecular biomarkers
Non-invasive and patient-friendly collection
Suitable for repeated longitudinal monitoring
Potential applications across neurology, oncology, ophthalmology, and systemic disease
The Future of Liquid Biopsy Is in the Eye
Our Platform
Why It Matters
Patent-pending diagnostic technologies
International Scientific Advisory Board
Growing network of academic and clinical collaborations
Founded by a physician-scientist with over two decades of biomedical research experience
European deep-tech company developing next-generation molecular diagnostics
BioDrop combines proprietary biomarker collection, preservation chemistry, molecular analysis, and artificial intelligence into a unified diagnostic platform.
Our approach is designed to support:
Standardized biomarker collection
Preservation of molecular integrity
Multi-omics research applications
AI-assisted interpretation of complex biological data
Advancing Precision Diagnostics
Early detection remains one of the greatest challenges in modern medicine. Many diseases are diagnosed only after symptoms appear, when treatment options may already be limited.
BioDrop is developing technologies that enable standardized, non-invasive molecular sampling, helping unlock biological information that could support earlier detection, more precise monitoring, and future advances in personalized medicine.
Current diagnostic approaches often involve:
Invasive sampling procedures
Hospital-based testing
Delayed detection after clinical symptoms emerge
From sample collection to computational interpretation, BioDrop is building an integrated platform for the next generation of precision diagnostics.
BioDrop Solutions is developing a platform for non-invasive molecular diagnostics based on tear biopsy. By integrating standardized sample collection, biomarker preservation, and computational analysis, we aim to expand access to precision diagnostics while enabling new opportunities for multi-omics research and AI-assisted medicine.
Beyond Conventional Liquid Biopsy:
Transforming Tears into Diagnostic Innovations
BioDrop Solutions is developing an integrated platform for non-invasive molecular diagnostics based on tear biopsy. By combining proprietary biomaterial engineering, biomarker preservation, molecular analysis, and computational interpretation, we aim to expand the clinical potential of tear-derived biomarkers.
We are presenting a fresh and innovative approach:
Standardized tear biopsy using proprietary biomaterials
Preservation of molecular integrity during collection and transport
Compatibility with multi-omics and AI-enabled analysis
Designed to support scalable research and future clinical translation
Initial Clinical Focus
BioDrop's initial development program is focused on glioma, where improved access to non-invasive molecular biomarkers could address a significant unmet clinical need. The underlying platform is designed to support future applications across neurodegenerative, ophthalmological, oncological, and systemic diseases as scientific validation expands.
Let's Advance Precision Diagnostics Together
We welcome collaborations with researchers, clinicians, healthcare organizations, industry partners, and investors who share our vision of advancing non-invasive precision diagnostics.
